- ROUNDTABLE: Improving patient outcomes, controlling costs with OTCs
- Reports: Novartis exits vaccines and animal health while acquiring oncology business from GSK
- Novartis names new head of sales U.S.
- GSK, Novartis create an $11 billion consumer healthcare business
- Sandoz starts late-stage trial of Humira biosimilar
PRINCETON, N.J. — Sandoz has launched generic versions of treatments for Alzheimer’s disease, the generic pharmaceuticals division of Swiss drug maker Novartis said Wednesday.
Sandoz announced the launch of donepezil hydrochloride film-coated tablets and donepezil hydrochloride orally disintegrating tablets, which are generic versions of Eisai and Pfizer’s Aricept and Aricept ODT, respectively.
Donepezil hydrochloride film-coated and orally disintegrating tablets had sales of $2.3 billion in the 12-month period ended in March, according to IMS Health.